Chordia Therapeutics EBIT

The latest EBIT for 190A.T is $-1.4B as of May 2026. That compares with $-2B in the prior-year period — up 28.4% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Chordia Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, 190A.T's EBIT moved from $-2B to $-1.4B — a 28.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chordia Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, 190A.T currently prints $-1.4B for EBIT, while the sector average sits near $110B. That is roughly 101.3% below the sector mean. Large gaps often invite a closer look at Chordia Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-1.4B for 190A.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 190A.T's EBIT ($-1.4B), review year-over-year change from $-2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.